- Home
- AVTX vs CLLS Comparison
AVTX vs CLLS Comparison
Compare AVTX & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AVTX | CLLS |
|---|---|---|
| Founded | 2011 | 1999 |
| Country | United States | France |
| Employees | N/A | 222 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 339.9M | 384.3M |
| IPO Year | 2015 | 2014 |
Fundamental Metrics
Financial Performance| Metric | AVTX | CLLS |
|---|---|---|
| Price | $17.10 | $3.80 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 2 |
| Target Price | ★ $32.57 | $8.50 |
| AVG Volume (30 Days) | ★ 510.9K | 36.3K |
| Earning Date | 04-20-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 81.66 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $27,813,137.00 | N/A |
| Revenue This Year | N/A | $40.37 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 2312.27 | N/A |
| 52 Week Low | $3.39 | $1.10 |
| 52 Week High | $20.72 | $5.48 |
Technical Indicators
Market Signals| Indicator | AVTX | CLLS |
|---|---|---|
| Relative Strength Index (RSI) | 54.28 | 47.91 |
| Support Level | $15.36 | $3.41 |
| Resistance Level | $19.26 | $4.46 |
| Average True Range (ATR) | 1.36 | 0.16 |
| MACD | 0.07 | 0.00 |
| Stochastic Oscillator | 65.50 | 35.06 |
Price Performance
Historical ComparisonAbout AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.